Selected research
Industry Research
Hospital-Acquired Infections Assays Industry Research Report 2026
Market perspective
The global Hospital-Acquired Infections Assays market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Hospital-Acquired Infections Assays market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Hospital-Acquired Infections Assays market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Hospital-Acquired Infections Assays market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Hospital-Acquired Infections Assays include BIOMÉRIEUX, Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthcare Private Limited, BD (Becton, Dickinson and Company), Bioscience, Inc., QIAGEN, Thermo Fisher Scientific Inc. and Meridian Bioscience, Inc. and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Hospital-Acquired Infections Assays market in terms of revenue (US$ million) and, where applicable, service volume (Unit), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Unit) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Hospital-Acquired Infections Assays.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hospital-Acquired Infections Assays Market by Company
BIOMÉRIEUX
Abbott
F. Hoffmann-La Roche Ltd.
Siemens Healthcare Private Limited
BD (Becton, Dickinson and Company)
Bioscience, Inc.
QIAGEN
Thermo Fisher Scientific Inc.
Meridian Bioscience, Inc.
Hologic, Inc.
Hospital-Acquired Infections Assays Segment by Type
Blood Tests
Urinalysis
Hospital-Acquired Infections Assays Segment by Application
Urinary Tract Infections
Pneumonia
Surgical Site Infections
Bloodstream Infections
Other Hospital Infections
Hospital-Acquired Infections Assays Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hospital-Acquired Infections Assays market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hospital-Acquired Infections Assays and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hospital-Acquired Infections Assays.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Hospital-Acquired Infections Assays companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Blood Tests
- Urinalysis
Applications
- Urinary Tract Infections
- Pneumonia
- Surgical Site Infections
- Bloodstream Infections
- Other Hospital Infections
Companies covered
- BIOMÉRIEUX
- Abbott
- F. Hoffmann-La Roche Ltd.
- Siemens Healthcare Private Limited
- BD (Becton, Dickinson and Company)
- Bioscience, Inc.
- QIAGEN
- Thermo Fisher Scientific Inc.
- Meridian Bioscience, Inc.
- Hologic, Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Hospital-Acquired Infections Assays by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Blood Tests
- 2.2.3 Urinalysis
- 2.3 Hospital-Acquired Infections Assays by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Urinary Tract Infections
- 2.3.3 Pneumonia
- 2.3.4 Surgical Site Infections
- 2.3.5 Bloodstream Infections
- 2.3.6 Other Hospital Infections
- 2.4 Assumptions and Limitations
3 Hospital-Acquired Infections Assays Breakdown Data by Type
- 3.1 Global Hospital-Acquired Infections Assays Historic Market Size by Type (2021-2026)
- 3.2 Global Hospital-Acquired Infections Assays Forecasted Market Size by Type (2027-2032)
4 Hospital-Acquired Infections Assays Breakdown Data by Application
- 4.1 Global Hospital-Acquired Infections Assays Historic Market Size by Application (2021-2026)
- 4.2 Global Hospital-Acquired Infections Assays Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Hospital-Acquired Infections Assays Market Perspective (2021-2032)
- 5.2 Global Hospital-Acquired Infections Assays Growth Trends by Region
- 5.2.1 Global Hospital-Acquired Infections Assays Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Hospital-Acquired Infections Assays Historic Market Size by Region (2021-2026)
- 5.2.3 Hospital-Acquired Infections Assays Forecasted Market Size by Region (2027-2032)
- 5.3 Hospital-Acquired Infections Assays Market Dynamics
- 5.3.1 Hospital-Acquired Infections Assays Industry Trends
- 5.3.2 Hospital-Acquired Infections Assays Market Drivers
- 5.3.3 Hospital-Acquired Infections Assays Market Challenges
- 5.3.4 Hospital-Acquired Infections Assays Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Hospital-Acquired Infections Assays Players by Revenue
- 6.1.1 Global Top Hospital-Acquired Infections Assays Players by Revenue (2021-2026)
- 6.1.2 Global Hospital-Acquired Infections Assays Revenue Market Share by Players (2021-2026)
- 6.2 Global Hospital-Acquired Infections Assays Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Hospital-Acquired Infections Assays Head Office and Area Served
- 6.4 Global Hospital-Acquired Infections Assays Players, Product Type & Application
- 6.5 Global Hospital-Acquired Infections Assays Manufacturers Established Date
- 6.6 Global Hospital-Acquired Infections Assays Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Hospital-Acquired Infections Assays Market Size (2021-2032)
- 7.2 North America Hospital-Acquired Infections Assays Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Hospital-Acquired Infections Assays Market Size by Country (2021-2026)
- 7.4 North America Hospital-Acquired Infections Assays Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Hospital-Acquired Infections Assays Market Size (2021-2032)
- 8.2 Europe Hospital-Acquired Infections Assays Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Hospital-Acquired Infections Assays Market Size by Country (2021-2026)
- 8.4 Europe Hospital-Acquired Infections Assays Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Hospital-Acquired Infections Assays Market Size (2021-2032)
- 9.2 Asia-Pacific Hospital-Acquired Infections Assays Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Hospital-Acquired Infections Assays Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Hospital-Acquired Infections Assays Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Hospital-Acquired Infections Assays Market Size (2021-2032)
- 10.2 South America Hospital-Acquired Infections Assays Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Hospital-Acquired Infections Assays Market Size by Country (2021-2026)
- 10.4 South America Hospital-Acquired Infections Assays Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Hospital-Acquired Infections Assays Market Size (2021-2032)
- 11.2 Middle East & Africa Hospital-Acquired Infections Assays Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Hospital-Acquired Infections Assays Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Hospital-Acquired Infections Assays Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 BIOMÉRIEUX
- 12.1.1 BIOMÉRIEUX Company Information
- 12.1.2 BIOMÉRIEUX Business Overview
- 12.1.3 BIOMÉRIEUX Revenue in Hospital-Acquired Infections Assays Business (2021-2026)
- 12.1.4 BIOMÉRIEUX Hospital-Acquired Infections Assays Product Portfolio
- 12.1.5 BIOMÉRIEUX Recent Developments
- 12.2 Abbott
- 12.2.1 Abbott Company Information
- 12.2.2 Abbott Business Overview
- 12.2.3 Abbott Revenue in Hospital-Acquired Infections Assays Business (2021-2026)
- 12.2.4 Abbott Hospital-Acquired Infections Assays Product Portfolio
- 12.2.5 Abbott Recent Developments
- 12.3 F. Hoffmann-La Roche Ltd.
- 12.3.1 F. Hoffmann-La Roche Ltd. Company Information
- 12.3.2 F. Hoffmann-La Roche Ltd. Business Overview
- 12.3.3 F. Hoffmann-La Roche Ltd. Revenue in Hospital-Acquired Infections Assays Business (2021-2026)
- 12.3.4 F. Hoffmann-La Roche Ltd. Hospital-Acquired Infections Assays Product Portfolio
- 12.3.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 12.4 Siemens Healthcare Private Limited
- 12.4.1 Siemens Healthcare Private Limited Company Information
- 12.4.2 Siemens Healthcare Private Limited Business Overview
- 12.4.3 Siemens Healthcare Private Limited Revenue in Hospital-Acquired Infections Assays Business (2021-2026)
- 12.4.4 Siemens Healthcare Private Limited Hospital-Acquired Infections Assays Product Portfolio
- 12.4.5 Siemens Healthcare Private Limited Recent Developments
- 12.5 BD (Becton, Dickinson and Company)
- 12.5.1 BD (Becton, Dickinson and Company) Company Information
- 12.5.2 BD (Becton, Dickinson and Company) Business Overview
- 12.5.3 BD (Becton, Dickinson and Company) Revenue in Hospital-Acquired Infections Assays Business (2021-2026)
- 12.5.4 BD (Becton, Dickinson and Company) Hospital-Acquired Infections Assays Product Portfolio
- 12.5.5 BD (Becton, Dickinson and Company) Recent Developments
- 12.6 Bioscience, Inc.
- 12.6.1 Bioscience, Inc. Company Information
- 12.6.2 Bioscience, Inc. Business Overview
- 12.6.3 Bioscience, Inc. Revenue in Hospital-Acquired Infections Assays Business (2021-2026)
- 12.6.4 Bioscience, Inc. Hospital-Acquired Infections Assays Product Portfolio
- 12.6.5 Bioscience, Inc. Recent Developments
- 12.7 QIAGEN
- 12.7.1 QIAGEN Company Information
- 12.7.2 QIAGEN Business Overview
- 12.7.3 QIAGEN Revenue in Hospital-Acquired Infections Assays Business (2021-2026)
- 12.7.4 QIAGEN Hospital-Acquired Infections Assays Product Portfolio
- 12.7.5 QIAGEN Recent Developments
- 12.8 Thermo Fisher Scientific Inc.
- 12.8.1 Thermo Fisher Scientific Inc. Company Information
- 12.8.2 Thermo Fisher Scientific Inc. Business Overview
- 12.8.3 Thermo Fisher Scientific Inc. Revenue in Hospital-Acquired Infections Assays Business (2021-2026)
- 12.8.4 Thermo Fisher Scientific Inc. Hospital-Acquired Infections Assays Product Portfolio
- 12.8.5 Thermo Fisher Scientific Inc. Recent Developments
- 12.9 Meridian Bioscience, Inc.
- 12.9.1 Meridian Bioscience, Inc. Company Information
- 12.9.2 Meridian Bioscience, Inc. Business Overview
- 12.9.3 Meridian Bioscience, Inc. Revenue in Hospital-Acquired Infections Assays Business (2021-2026)
- 12.9.4 Meridian Bioscience, Inc. Hospital-Acquired Infections Assays Product Portfolio
- 12.9.5 Meridian Bioscience, Inc. Recent Developments
- 12.10 Hologic, Inc.
- 12.10.1 Hologic, Inc. Company Information
- 12.10.2 Hologic, Inc. Business Overview
- 12.10.3 Hologic, Inc. Revenue in Hospital-Acquired Infections Assays Business (2021-2026)
- 12.10.4 Hologic, Inc. Hospital-Acquired Infections Assays Product Portfolio
- 12.10.5 Hologic, Inc. Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst